Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Target and tissue selectivity of PROTAC degraders
Robert G. Guenette, Seung Wook Yang, Jaeki Min, et al.
Chemical Society Reviews (2022) Vol. 51, Iss. 14, pp. 5740-5756
Closed Access | Times Cited: 146

Showing 26-50 of 146 citing articles:

Targeted protein degradation: advances in drug discovery and clinical practice
Guangcai Zhong, Xiaoyu Chang, Weilin Xie, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 13
Homo-BacPROTAC-induced degradation of ClpC1 as a strategy against drug-resistant mycobacteria
Lukas Junk, Volker M. Schmiedel, Somraj Guha, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 10
Restraining the power of Proteolysis Targeting Chimeras in the cage: A necessary and important refinement for therapeutic safety
Renshuai Zhang, Songbo Xie, Jie Ran, et al.
Journal of Cellular Physiology (2024) Vol. 239, Iss. 5
Closed Access | Times Cited: 10
Repurposing AS1411 for constructing ANM-PROTACs
Xuekun Fu, Jin Li, Xinxin Chen, et al.
Cell chemical biology (2024) Vol. 31, Iss. 7, pp. 1290-1304.e7
Closed Access | Times Cited: 10
Targeted Protein Degradation: Current and Emerging Approaches for E3 Ligase Deconvolution
Yufeng Xiao, Yaxia Yuan, Yi Liu, et al.
Journal of Medicinal Chemistry (2024)
Closed Access | Times Cited: 8
Selective degradation of multimeric proteins by TRIM21-based molecular glue and PROTAC degraders
Panrui Lu, Y. Cheng, Lei Xue, et al.
Cell (2024)
Closed Access | Times Cited: 8
Modulating the phosphorylation status of target proteins through bifunctional molecules
Qindi He, Zhijie Wang, Rongrong Wang, et al.
Drug Discovery Today (2025), pp. 104307-104307
Closed Access | Times Cited: 1
Overcoming cancer therapy resistance: From drug innovation to therapeutics
Jinrui Wei, Meng‐Yi Lu, Tian‐Hua Wei, et al.
Drug Resistance Updates (2025) Vol. 81, pp. 101229-101229
Closed Access | Times Cited: 1
Leveraging aptamers for targeted protein degradation
Zhihao Yang, Qiuxiang Pang, Jun Zhou, et al.
Trends in Pharmacological Sciences (2023) Vol. 44, Iss. 11, pp. 776-785
Closed Access | Times Cited: 21
The recent advance of Interleukin-1 receptor associated kinase 4 inhibitors for the treatment of inflammation and related diseases
Yi‐Ru Bai, Weiguang Yang, Xuehui Hou, et al.
European Journal of Medicinal Chemistry (2023) Vol. 258, pp. 115606-115606
Closed Access | Times Cited: 20
Recent advances of targeting nicotinamide phosphoribosyltransferase (NAMPT) for cancer drug discovery
He Tang, Lin Wang, Tianyu Wang, et al.
European Journal of Medicinal Chemistry (2023) Vol. 258, pp. 115607-115607
Closed Access | Times Cited: 20
PROTACs in the Management of Prostate Cancer
Yedla Poornachandra, Ahmad O. Babalghith, Vindhya Vasini Andra, et al.
Molecules (2023) Vol. 28, Iss. 9, pp. 3698-3698
Open Access | Times Cited: 17
Dual‐Programmable Semiconducting Polymer NanoPROTACs for Deep‐Tissue Sonodynamic‐Ferroptosis Activatable Immunotherapy
Fengshuo Wang, Guoqiang Dong, Mengbin Ding, et al.
Small (2023) Vol. 20, Iss. 8
Closed Access | Times Cited: 17
Recent progress in degradation of membrane proteins by PROTACs and alternative targeted protein degradation techniques
Siyu Chen, Jingliang Cui, Haiyan Chen, et al.
European Journal of Medicinal Chemistry (2023) Vol. 262, pp. 115911-115911
Closed Access | Times Cited: 17
Peptide-based PROTACs: Current Challenges and Future Perspectives
Huidan Wang, Miao Chen, Xiaoyuan Zhang, et al.
Current Medicinal Chemistry (2023) Vol. 31, Iss. 2, pp. 208-222
Closed Access | Times Cited: 16
JAK1/JAK2 degraders based on PROTAC for topical treatment of atopic dermatitis
Junchao Wu, Lisha Li, Quangang Zhu, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 171, pp. 116167-116167
Open Access | Times Cited: 6
High‐Throughput Miniaturized Synthesis of PROTAC‐Like Molecules
Ye Tian, Maximilian Seifermann, Liana Bauer, et al.
Small (2024) Vol. 20, Iss. 26
Closed Access | Times Cited: 6
Recent Progress in DNA Damage Response-Targeting PROTAC Degraders
Binbin Cheng, Xiaoting Fei, Zongbao Ding, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 9, pp. 6906-6921
Closed Access | Times Cited: 6
Synthetic lethality: targeting the SMARCA2 bromodomain for degradation in SMARCA4-deficient tumors – a review of patent literature from 2019–June 2023
Esther C. Y. Lee, Kyle D. Reichl, Ariamala Gopalsamy
Expert Opinion on Therapeutic Patents (2024) Vol. 34, Iss. 4, pp. 211-229
Closed Access | Times Cited: 6
PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer
Hongyan Zhang, Longlong Zhang, Yuna He, et al.
Cancer Letters (2024) Vol. 598, pp. 217112-217112
Closed Access | Times Cited: 6
Targeted protein degradation using chimeric human E2 ubiquitin-conjugating enzymes
Jonathan D. Taylor, Nathalie Barrett, Sergio Martínez Cuesta, et al.
Communications Biology (2024) Vol. 7, Iss. 1
Open Access | Times Cited: 6
Structure-based design of selective, orally available salt-inducible kinase inhibitors that stimulate bone formation in mice
Tadatoshi Sato, Christian Castro, Sung-Hee Yoon, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 50
Open Access | Times Cited: 25
Discovery of Ligands for TRIM58, a Novel Tissue-Selective E3 Ligase
Klemens Hoegenauer, Shaojian An, Jake Axford, et al.
ACS Medicinal Chemistry Letters (2023) Vol. 14, Iss. 12, pp. 1631-1639
Closed Access | Times Cited: 15
Antibody-Proteolysis Targeting Chimera Conjugate Enables Selective Degradation of Receptor-Interacting Serine/Threonine-Protein Kinase 2 in HER2+ Cell Lines
Karina Chan, Preethi S. Sathyamurthi, Markus A. Queisser, et al.
Bioconjugate Chemistry (2023) Vol. 34, Iss. 11, pp. 2049-2054
Open Access | Times Cited: 14
Beyond canonical PROTAC: biological targeted protein degradation (bioTPD)
Huifang Wang, Runhua Zhou, Fushan Xu, et al.
Biomaterials Research (2023) Vol. 27, Iss. 1
Open Access | Times Cited: 13

Scroll to top